Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2019 (Specifically dated February 5, 2019)
Business Context: The filing discloses a capital raise via an on-market placement to fund current clinical development, research programs, and working capital. The company is an Australian biotechnology entity.
Key Financial Metrics and Capital Structure
Capital Raise Details:
- Securities Issued: 1,912,440 Fully Paid Ordinary Shares
- Issue Price: AUD 0.0403 per share
- Total Proceeds: Approximately AUD 77,071 (Calculated: 1,912,440 shares * AUD 0.0403)
- Issue Date: February 4, 2019
Capital Structure (Post-Issue):
- Quoted Ordinary Shares: 554,676,850
- Unlisted Options: 25,300,000 (Various strike prices ranging from AUD 0.07 to AUD 0.27; expiries between 2020 and 2023)
Financial Performance: The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This document is a regulatory notice regarding a share issuance, not a financial results report.
Material Changes Versus Prior Period
Share Capital Increase: The company increased its issued share capital by 1,912,440 shares. This issuance was conducted under Rule 7.1A (eligible entity placement capacity) following shareholder approval granted on November 16, 2018.
Placement Capacity:
- Remaining capacity under Rule 7.1: 62,844,458 shares
- Remaining capacity under Rule 7.1A: 53,697,505 shares
Guidance, Outlook, and Management Commentary
Use of Proceeds: Funds raised are designated for clinical development, research programs, and working capital.
Future Issuances: Management indicated this is an "on-going placement" and that more tranches will be allotted in the future.
Risks and Contingencies: The filing confirms compliance with the Corporations Act and states there is no "excluded information" required to be disclosed. No specific operational risks or contingencies were detailed in this specific notice.
Important Facts for Investor Verification
- Company Name Discrepancy: The request metadata lists "Alterity Therapeutics Ltd," but the filing is explicitly for "Prana Biotechnology Limited." Investors must verify if these entities are related or if the metadata is incorrect.
- Dilution Impact: Verify the impact of the 1.9 million new shares on existing holdings, noting the low issue price of AUD 0.0403.
- Option Overhang: Confirm the total number of unlisted options (25.3 million) and their exercise prices relative to the current market price to assess potential future dilution.
- Capital Raise Continuity: Monitor for subsequent announcements regarding the "more tranches" mentioned by management.
- Financial Health: As this filing contains no financial statements, investors must refer to the most recent Form 20-F or ASX announcements for actual revenue, cash burn, and liquidity status.